Silvia Coretti1, Paola Codella2, Federica Romano2, Matteo Ruggeri2, Americo Cicchetti3. 1. Postgraduate School of Health Economics and Management,Università Cattolica del Sacro Cuore,Rome,Italysilvia.coretti@unicatt.it. 2. Postgraduate School of Health Economics and Management,Università Cattolica del Sacro Cuore,Rome,Italy. 3. Director of Postgraduate School of Health Economics and Management,Università Cattolica del Sacro Cuore,Rome,Italy.
Abstract
OBJECTIVES: Herpes zoster (HZ) is characterized by a painful skin rash. Its main complication is postherpetic neuralgia (PHN), pain persisting or occurring after the rash onset. HZ treatment aims to reduce acute pain, impede the onset complications, and disease progression. The aim of this study was to assess the cost-effectiveness of HZ vaccination compared with no vaccination strategy, within the Italian context. METHODS: The natural history of HZ and PHN was mapped through a Markov model with lifetime horizon. A population of patients aged between 60 and 79 years was hypothesized. Third party payer (Italian National Health Service, I-NHS) and societal perspectives were adopted. Data were derived from literature. RESULTS AND CONCLUSIONS: The incremental cost-effectiveness ratio of the vaccination equaled EUR 11,943 per quality-adjusted life-year (QALY) under the I-NHS perspective and EUR 11,248 per QALY under the societal perspective. Considering a cost-effectiveness threshold of EUR 30,000/QALY, the multi-way sensitivity analysis showed that vaccination is cost-effective regardless of the perspective adopted, in 99 percent of simulations.
OBJECTIVES: Herpes zoster (HZ) is characterized by a painful skin rash. Its main complication is postherpetic neuralgia (PHN), pain persisting or occurring after the rash onset. HZ treatment aims to reduce acute pain, impede the onset complications, and disease progression. The aim of this study was to assess the cost-effectiveness of HZ vaccination compared with no vaccination strategy, within the Italian context. METHODS: The natural history of HZ and PHN was mapped through a Markov model with lifetime horizon. A population of patients aged between 60 and 79 years was hypothesized. Third party payer (Italian National Health Service, I-NHS) and societal perspectives were adopted. Data were derived from literature. RESULTS AND CONCLUSIONS: The incremental cost-effectiveness ratio of the vaccination equaled EUR 11,943 per quality-adjusted life-year (QALY) under the I-NHS perspective and EUR 11,248 per QALY under the societal perspective. Considering a cost-effectiveness threshold of EUR 30,000/QALY, the multi-way sensitivity analysis showed that vaccination is cost-effective regardless of the perspective adopted, in 99 percent of simulations.
Authors: Edward T Chiyaka; Van T Nghiem; Lu Zhang; Abhishek Deshpande; Patricia Dolan Mullen; Phuc Le Journal: Pharmacoeconomics Date: 2019-02 Impact factor: 4.558
Authors: Antonio Volpi; Sara Boccalini; Silvia Dari; Christopher Clarke; Desmond Curran; Idalba Loiacono; Andrea Pitrelli; Anna Puggina; Roberta Tosatto; Desirée Van Oorschot; Elisabetta Franco Journal: Hum Vaccin Immunother Date: 2019-09-24 Impact factor: 3.452
Authors: Sean Matthews; Antonio De Maria; Marco Passamonti; Giovanni Ristori; Idalba Loiacono; Anna Puggina; Desmond Curran Journal: Open Forum Infect Dis Date: 2019-01-12 Impact factor: 3.835